Crescent Biopharma, Inc.
NASDAQ:CBIOBiotechnology
-$0.49 today
- Market cap
- $482.30M
- Beta
- 1.15
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$5.33
Volume 0.33M
Average 0.28M
Returns on capital
Crescent Biopharma, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-75.8%
avg -26.6%
ROIC
-74.6%
avg -72.7%
ROA
-64.1%
avg -59.7%
Analysis
ROA is currently the strongest return metric at -64.1% versus its period average of -59.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Joshua T. Brumm | Chief Executive Officer & Director | USD 1.25M | 48 | 271.76K | 0.99% |
Jonathan McNeill | President & Chief Operating Officer | USD 871.68K | 41 | 134.59K | 0.49% |
Ellie Im | Chief Medical Officer | USD 847.84K | 48 | — | — |
Wenjie Cheng | Senior Vice President of Technical Operations | — | — | — | — |
Christopher Doughty | Chief Business Officer | — | 38 | — | — |
Richard William Scalzo | Chief Financial Officer | — | 40 | 19.73K | 0.07% |
Ryan Lynch | Senior Vice President of Finance, Treasurer & Chief Accounting Officer | — | 42 | 13.63K | 0.05% |
Amy Reilly | Chief Communications Officer | — | 52 | — | — |
Barbara H. Bispham | General Counsel & Corporate Secretary | — | 39 | — | — |
Jan Pinkas | Chief Scientific Officer | — | 57 | 21.58K | 0.08% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$30.61M
Sells
16
$1.51M
Net Transaction Value
+$29.10M
Net buying
Most Active
Fairmount Funds Management LLC
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 18, 26Sep 18, 2026 | Brumm Joshua T Direct | Sell | $131K$130,956.27 |
| Sep 18, 26Sep 18, 2026 | McNeill Jonathan Direct | Sell | $64.1K$64,149.69 |
| Sep 16, 26Sep 16, 2026 | Bispham Barbara Harlin Direct | Sell | $11.1K$11,098.00 |
| Sep 16, 26Sep 16, 2026 | Brumm Joshua T Direct | Sell | $28.8K$28,819.00 |
| Sep 16, 26Sep 16, 2026 | McNeill Jonathan Direct | Sell | $13.1K$13,084.90 |
| Sep 16, 26Sep 16, 2026 | Im Ellie Eunkyung Direct | Sell | $11.2K$11,151.70 |
| Sep 16, 26Sep 16, 2026 | Scalzo Richard William Direct | Sell | $10.2K$10,167.20 |
| Sep 16, 26Sep 16, 2026 | Lynch Ryan Direct | Sell | $4.3K$4,296.00 |
| Sep 16, 26Sep 16, 2026 | Pinkas Jan Direct | Sell | $11.8K$11,778.20 |
| Jul 16, 26Jul 16, 2026 | Fairmount Funds Management LLC Indirect | Buy | $525.9$525.90 |
1–10 of 20
Summary
Insiders reported 4 buys worth $30.61M and 16 sells worth $1.51M over the last 12 months. That adds up to net buying of $29.10M. Fairmount Funds Management LLC was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +424.9% | +67.3% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +424.9% over three years. Forward estimates point to Revenue at +67.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Crescent Biopharma, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CBIO's management, answered from reported figures.
Who manages CBIO?
Crescent Biopharma, Inc. (CBIO) lists 10 active executives. The top listed executive is Jonathan McNeill, President & Chief Operating Officer.
Are CBIO insiders buying or selling?
Recent insider activity shows net buying of $46.84M.
Continue the stock analysis
Jump to another research area for this company.